Abstract

Inflammatory bowel diseases (IBDs) may be associated with extra-intestinal manifestations. Among these, mucocutaneous manifestations are relatively frequent, often difficult to diagnose and treat, and may complicate the course of the underlying disease. In the present review, a summary of the most relevant literature on the dermatologic manifestations occurring in patients with inflammatory bowel diseases has been reviewed. The following dermatological manifestations associated with IBDs have been identified: (i) specific manifestations with the same histological features of the underlying IBD (occurring only in Crohn’s disease); (ii) cutaneous disorders associated with IBDs (such as aphthous stomatitis, erythema nodosum, psoriasis, epidermolysis bullosa acquisita); (iii) reactive mucocutaneous manifestations of IBDs (such as pyoderma gangrenosum, Sweet’s syndrome, bowel-associated dermatosis-arthritis syndrome, aseptic abscess ulcers, pyodermatitis–pyostomatitis vegetans, etc.); (iv) mucocutaneous conditions secondary to treatment (including injection site reactions, infusion reactions, paradoxical reactions, eczematous and psoriasis-like reactions, cutaneous infections, and cutaneous malignancies); (v) manifestations due to nutritional malabsorption (such as stomatitis, glossitis, angular cheilitis, pellagra, scurvy, purpura, acrodermatitis enteropathica, phrynoderma, seborrheic-type dermatitis, hair and nail abnormalities). An accurate dermatological examination is essential in all IBD patients, especially in candidates to biologic therapies, in whom drug-induced cutaneous reactions may assume marked clinical relevance.

Highlights

  • Inflammatory bowel diseases (IBDs) are a group of disorders characterized by chronic relapsing intestinal inflammation that includes two main entities—Crohn’s disease (CD)and ulcerative colitis (UC)

  • Up to 40% of IBD cases may be complicated by extra-intestinal manifestations (EIM) and in some large series of studies, the prevalence of EIMs is higher in CD compared to UC [2]

  • A prospective study conducted by Yüksel et al in 352 IBD patients in a 4.5-year period concluded that cutaneous manifestations had a prevalence of 9.3%

Read more

Summary

Introduction

Inflammatory bowel diseases (IBDs) are a group of disorders characterized by chronic relapsing intestinal inflammation that includes two main entities—Crohn’s disease (CD). Up to 40% of IBD cases may be complicated by EIMs and in some large series of studies, the prevalence of EIMs is higher in CD compared to UC [2]. The skin is one of the most commonly involved organs, and cutaneous manifestations may be present in more than 10% of these patients [2,8], higher rates have been documented [9,10]. A prospective study conducted by Yüksel et al in 352 IBD patients in a 4.5-year period concluded that cutaneous manifestations had a prevalence of 9.3%. The main goal of this review is to summarize the most recent knowledge regarding mucocutaneous manifestations related to IBD, focusing on secondary cutaneous manifestations due to concomitant drugs used for the treatment of these conditions

Experimental Section
Classification
Metastatic Crohn’s Disease
Mucocutaneous
Mucocutaneous Disorders Associated with IBD
Aphthous Stomatitis
Erythema Nodosum forms
Psoriasis
Epidermolysis Bullosa Acquisita
Reactive Mucocutaneous Manifestation of IBD
Pyoderma Gangrenosum
Sweet’s Syndrome
Bowel-Associated Dermatosis-Arthritis Syndrome
Aseptic Abscess Syndrome
Pyodermatitis–pyostomatitis Vegetans
SAPHO and PAPA Syndromes
Mucocutaneous Conditions Secondary to IBD Treatment
Adverse Mucocutaneous
Infectious
Manifestations Due to Nutritional Malabsorption
Findings
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call